ProQR Therapeutics (NASDAQ:PRQR) & Krystal Biotech (NASDAQ:KRYS) Head-To-Head Review

ProQR Therapeutics (NASDAQ:PRQR) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Valuation & Earnings

This table compares ProQR Therapeutics and Krystal Biotech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$18.36 million	10.67	-$47.73 million	($0.46)	-4.04
Krystal Biotech	$389.13 million	26.40	$204.83 million	$7.98	43.48

Krystal Biotech has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for ProQR Therapeutics and Krystal Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1	1	6	0	2.62
Krystal Biotech	0	2	10	1	2.92

ProQR Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 303.23%. Krystal Biotech has a consensus target price of $365.40, indicating a potential upside of 5.30%. Given ProQR Therapeutics’ higher probable upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than Krystal Biotech.

Volatility & Risk

ProQR Therapeutics has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Profitability

This table compares ProQR Therapeutics and Krystal Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Krystal Biotech	54.82%	19.34%	17.65%

Summary

Krystal Biotech beats ProQR Therapeutics on 14 of the 15 factors compared between the two stocks.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.